IL5RA and chronic rhinosinusitis with nasal polyps: In CRS, agents currently approved or under assessment for CRSwNP target components of the Type 2 inflammatory pathway, notably interleukin (IL)-4, IL-5 and IL-13, IL-5R, IL-33, and immunoglobulin (Ig)E [9].